Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0022, a MET/CSF1R/SRC inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in Phase 1/2 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, a preclinical ALK inhibitor for advanced non-small-cell lung cancer. The company was founded in 2013 and is headquartered in San Diego, California.
IPO Year: 2019
Exchange: NASDAQ
Website: tptherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/20/2022 | $58.00 | Buy | BofA Securities |
| 3/1/2022 | $50.00 → $45.00 | Hold | Stifel |
| 2/10/2022 | $120.00 → $85.00 | Overweight | Wells Fargo |
| 1/21/2022 | $115.00 → $105.00 | Outperform | Oppenheimer |
| 12/7/2021 | Outperform | Cowen & Co. | |
| 11/10/2021 | $150.00 → $115.00 | Outperform | Oppenheimer |
| 10/12/2021 | $178.00 → $162.00 | Buy | HC Wainwright & Co. |
| 10/11/2021 | Market Outperform → Market Perform | JMP Securities | |
| 9/30/2021 | $75.00 | Hold | Stifel |
NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the appointment of Steve Sabus as Chief Commercial Officer, effective as of May 31, 2022. Prior to Turning Point, Mr. Sabus spent 15 years in roles with increasing levels of sales responsibility at Astellas Pharma, most recently serving as the Head of Oncology leading a group of over 300 team members. In this role he provided executive leadership to scale the company's $3 billion U.S. oncology franchise by launching and growing new products. His achievements include su
SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Brian Sun, M.S., J.D. as its incoming Senior Vice President and General Counsel, effective as of April 11, 2022. Mr. Sun currently serves as Senior Vice President and General Counsel at Sorrento Therapeutics, Inc, a Nasdaq-listed company, where he leads the legal function and team. Previously, he worked at Prometheus Laboratories and Hologic and served as outside general counsel to early-stage biotechnology companies. Earlier in his career, Mr
MORRISVILLE, N.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it has appointed two new independent directors, Barbara W. Bodem and Alfonso G. Zulueta, to its Board of Directors. "We are excited to welcome Barbara and Alfonso to the Syneos Health Board," said John Dineen, Chair of the Syneos Health Board of Directors. "Barbara's deep financial expertise combined with Alfonso's expansive industry knowledge and international experience bring important perspectives to an already strong Board. These two leaders will enhance the composition of our Board and support continued successful overs
SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Adam Levy, Ph.D., MBA, as senior vice president of Investor Relations and Corporate Communications, effective today. Dr. Levy brings more than 20 years of experience to Turning Point, including a strong background in investor relations, corporate strategy and communications. Prior to joining Turning Point, he served as executive vice president of Corporate Development and Investor Relations at Ziopharm Oncology. Previously, Dr. Levy served as executive directo
SAN DIEGO, June 29, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Paolo Tombesi as executive vice president and CFO, effective July 26. Mr. Tombesi brings 30 years of global financial and accounting experience to Turning Point from multiple prior financial leadership roles within biotech and pharmaceutical companies, most recently serving as CFO of Epizyme, Inc. "Paolo brings very valuable global financial experience to our growing team, particularly in supporting commercial organizations and product launches," said Athena Countouriotis, M.D., pre
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of former Celgene chairman and CEO, Mark Alles, to chair its board of directors. Garry Nicholson, who is currently the interim chair, will remain on the board. Mr. Alles is an accomplished biopharmaceutical executive who led successful global oncology-focused organizations over his more than three-decade career, which includes driving growth and innovation during 15 years at Celgene until its $74-billion acquisition by Bristol Myers Squibb in 2019. President and
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Kumar Srinivasan, Ph.D., MBA, as executive vice president and chief business officer, effective June 1. Dr. Srinivasan has over 20 years of experience in pharmaceutical and biotechnology companies, most recently as vice president and global head of business development for the BioPharmaceutical business unit of AstraZeneca. "As we advance now four clinical stage drug candidates and enhance our pipeline for the future, Kumar brings deep expertise to help guide o